Show simple item record

dc.contributor.authorAcebedo Martínez, Francisco Javier
dc.contributor.authorAlarcón Payer, Carolina
dc.contributor.authorDi Crisci, Milena
dc.contributor.authorDomínguez Martín, Alicia 
dc.contributor.authorGómez Morales, Jaime
dc.contributor.authorChoquesillo Lazarte, Duane
dc.date.accessioned2022-02-01T09:09:22Z
dc.date.available2022-02-01T09:09:22Z
dc.date.issued2021-12-13
dc.identifier.citationAcebedo-Martínez, F.J... [et al.]. Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape. Pharmaceutics 2021, 13, 2140. [https://doi.org/10.3390/pharmaceutics13122140]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/72580
dc.descriptionThis research was funded by Spanish Agencia Estatal de Investigacion of the Ministerio de Ciencia, Innovacion y Universidades (MICIU) and co-funded with FEDER, UE, project no. PGC2018-102047-B-I00 (MCIU/AEI/FEDER, UE) and project B-FQM-478-UGR20 (FEDER-Universidad de Granada, Spain). AF thanks MCIU/AEI of Spain (project PID2020-115637GB-I00, FEDER, UE funds)for financial support.es_ES
dc.description.abstractAny time the pharmaceutical industry develops a new drug, potential polymorphic events must be thoroughly described, because in a crystalline pharmaceutical solid, different arrangements of the same active pharmaceutical ingredient can yield to very different physicochemical properties that might be crucial for its efficacy, such as dissolution, solubility, or stability. Polymorphism in cocrystal formulation cannot be neglected, either. In this work, two different cocrystal polymorphs of the non-steroidal anti-inflammatory drug niflumic acid and caffeine are reported. They have been synthesized by mechanochemical methods and thoroughly characterized in solid-state by powder and single crystal X-ray diffraction respectively, as well as other techniques such as thermal analyses, infrared spectroscopy and computational methods. Both theoretical and experimental results are in agreement, confirming a conformational polymorphism. The polymorph NIF–CAF Form I exhibits improved solubility and dissolution rate compared to NIF–CAF Form II, although Form II is significantly more stable than Form I. The conditions needed to obtain these polymorphs and their transition have been carefully characterized, revealing an intricate system.es_ES
dc.description.sponsorshipSpanish Agencia Estatal de Investigacion of the Ministerio de Ciencia, Innovacion y Universidades (MICIU)es_ES
dc.description.sponsorshipEuropean Commission PGC2018-102047-B-I00es_ES
dc.description.sponsorshipFEDER-Universidad de Granada, Spain B-FQM-478-UGR20es_ES
dc.description.sponsorshipMCIU/AEI of Spain PID2020-115637GB-I00 PRE2019-088832es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectCocrystal polymorphismes_ES
dc.subjectNiflumic acides_ES
dc.subjectCaffeine es_ES
dc.subjectNSAIDses_ES
dc.subjectMechanochemical synthesises_ES
dc.titleNovel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscapees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/pharmaceutics13122140
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España